Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer


Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

In this episode of Speaking of Urology®, Amar Kishan, MD, highlights findings from phase 3 MIRAGE trial (NCT04384770), which compared Magnetic Resonance Imaging-guided stereotactic body radiotherapy with Computed Tomography-guided stereotactic body radiotherapy in localized prostate cancer. Kishan is an associate professor of radiation oncology and urology and the chief of genitourinary oncology for radiation oncology at University of California, Los Angeles.

Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.

Related Videos
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Paul E. Dato, MD, an expert on prostate cancer
Charles Parker, MD, answers a question during a Zoom video interview
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.